Last reviewed · How we verify

NCT05801068: PERIXa

Perioperative Management of Factor Xa Inhibitors

Active, enrolled NA Last updated 7 January 2025
What this trial tests

NA trial testing Factor Xa Inhibitor in Atrial Fibrillation in 2,500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 August 2020
Primary endpoint
15 May 2024
31 December 2025

Quick facts

Lead sponsorSeoul National University Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment2,500
Start date4 August 2020
Primary completion15 May 2024
Estimated completion31 December 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

20 and older, any sex, with Atrial Fibrillation or Anticoagulant-induced Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to analyze the safety and effectiveness of the discontinuation/resumption protocol of factor Xa inhibitors before and after invasive procedures/surgeries in non-valvular atrial fibrillation patients who are at risk of minor bleeding in actual clinical settings

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Perioperative Management in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Minor Bleeding Risk Procedure: Rationale and Protocol for the PERIXa Study.
    Kwon S, Lee SR, Choi EK, Lee KY, et al · · 2024 · cited 4× · PMID 38774425 · DOI 10.2147/vhrm.s455530

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05801068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing